In today’s briefing:
- Bristol-Myers Squibb: Acquisition of Turning Point Therapeutics & Other Developments
- Shenzhen Mindray Bio-Medical Electronics (300760.CH) 2022H1 – Waiting for the Next Jump in Valuation
Bristol-Myers Squibb: Acquisition of Turning Point Therapeutics & Other Developments
- Bristol-Myers has continued its efforts towards expanding its new product range, in-line franchises, pipeline, and carried out critical business growth initiatives.
- This result was fuelled by their in-line and new product portfolio’s 16% solid growth, which more than made up for their recent LOEs.
- In this report, we have carried out a fundamental analysis of the historical financial statements of the company.
Shenzhen Mindray Bio-Medical Electronics (300760.CH) 2022H1 – Waiting for the Next Jump in Valuation
- Mindray withstood the negative impact of pandemic/lockdown and continued to achieve solid growth in 2022H1 amid China’s “new infrastructure” projects and the recovery of overseas demand for routine medical care.
- The essence of falling shares is the process of optimistic high growth expectations returning to rationality,which takes time until the cyclical shocks brought by the receding of pandemic are digested.
- Mindray’s biggest alpha could be the change brought about by M&A. From the perspective of strategic development, the next jump in valuation is likely to depend on subsequent M&A performance.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars